Product Description
selected Mesenchymal stromal cells derived from human umbilical cord
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Belfast Health and Social Care Trust
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: ANCA Vasculitis|Kidney Diseases
Phase 2: Cholangitis, Sclerosing|Acute Respiratory Distress Syndrome|Hepatitis, Autoimmune
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02997878 |
Merlin | P2 |
Active, not recruiting |
Cholangitis, Sclerosing|Hepatitis, Autoimmune |
2023-11-23 |
2024-07-12 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2017-000584-33 |
Repair of ARDS by Stromal Cell Administration (REALIST) | P2 |
Unknown status |
Acute Respiratory Distress Syndrome |
2021-12-06 |
2022-03-13 |
Treatments |
|
ACTRN12619000486123p |
TXCoronavac | P3 |
Not yet recruiting |
ANCA Vasculitis|Kidney Diseases |
2021-02-01 |